129 related articles for article (PubMed ID: 21342029)
1. The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
Addeo R; Caraglia M
Expert Rev Anticancer Ther; 2011 Feb; 11(2):139-42. PubMed ID: 21342029
[No Abstract] [Full Text] [Related]
2. Molecularly targeted therapy in breast cancer: the new generation.
Nahleh ZA
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):100-4. PubMed ID: 18537752
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib in second-line treatment for metastatic breast cancer: rapid clinical benefit and long-term response.
De Tursi M; Carella C
Tumori; 2013; 99(6):261e-3e. PubMed ID: 24503799
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
[TBL] [Abstract][Full Text] [Related]
5. Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
Spraggs CF; Parham LR; Song K; Briley LP; Johnson T; Russo M; Tada H; du Bois A; Xu CF
Ann Oncol; 2015 Jul; 26(7):1515-7. PubMed ID: 25922065
[No Abstract] [Full Text] [Related]
6. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.
Melisko ME; Glantz M; Rugo HS
Nat Clin Pract Oncol; 2009 Jan; 6(1):25-33. PubMed ID: 18936791
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.
Azim HA; Azim HA
Future Oncol; 2012 Feb; 8(2):135-44. PubMed ID: 22335578
[TBL] [Abstract][Full Text] [Related]
8. [Advances in research on treatment of breast cancer with lapatinib].
Ma CD; Shen KW; Shen ZZ
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):321-4. PubMed ID: 18953827
[No Abstract] [Full Text] [Related]
9. Three new drugs available to fight kidney cancer.
Bankhead C
J Natl Cancer Inst; 2006 Sep; 98(17):1181-2. PubMed ID: 16954469
[No Abstract] [Full Text] [Related]
10. Lapatinib-associated toxicity and practical management recommendations.
Moy B; Goss PE
Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
[TBL] [Abstract][Full Text] [Related]
11. Are volumetric changes of brain metastases the best evaluation of efficacy?
Belkacémi Y; Kuten A
J Clin Oncol; 2008 Nov; 26(31):5137-8; author reply 5138-9. PubMed ID: 18838700
[No Abstract] [Full Text] [Related]
12. Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib.
Zeng H; Li X; Yao J; Zhu Y; Liu J; Yang Y; Qiang W
Urol Int; 2009; 83(4):482-5. PubMed ID: 19996660
[TBL] [Abstract][Full Text] [Related]
13. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
Tomasello G; Bedard PL; de Azambuja E; Lossignol D; Devriendt D; Piccart-Gebhart MJ
Crit Rev Oncol Hematol; 2010 Aug; 75(2):110-21. PubMed ID: 20004109
[TBL] [Abstract][Full Text] [Related]
14. Radiological response of brain metastases to novel tyrosine kinase inhibitor lapatinib.
Ammannagari N; Ahmed S; Patel A; Bravin EN
QJM; 2013 Sep; 106(9):869-70. PubMed ID: 23596263
[No Abstract] [Full Text] [Related]
15. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Jo Chien A; Rugo HS
Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
[No Abstract] [Full Text] [Related]
16. Brain metastasis in renal cell cancer responding to sunitinib.
Koutras AK; Krikelis D; Alexandrou N; Starakis I; Kalofonos HP
Anticancer Res; 2007; 27(6C):4255-7. PubMed ID: 18214028
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
Duchnowska R; Loibl S; Jassem J
Cancer Treat Rev; 2018 Jun; 67():71-77. PubMed ID: 29772459
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
Sardesai SD; Storniolo AM
Womens Health (Lond); 2015 Jun; 11(3):281-94. PubMed ID: 26102468
[TBL] [Abstract][Full Text] [Related]
19. American Society of Clinical Oncology Annual Meeting 2013.
Yaqub F
Lancet Respir Med; 2013 Jul; 1(5):360-1. PubMed ID: 24429195
[No Abstract] [Full Text] [Related]
20. Trials probe new agents for kidney cancer.
Hampton T
JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
[No Abstract] [Full Text] [Related]
[Next] [New Search]
